{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9ZAYHU9A/5a406c5e-65d6-40c5-a5b1-23e04dadd933/HTML","dcterms:extent":"42 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9ZAYHU9A/b4f6eca3-5f56-4e04-abb3-b88c151cf527/PDF","dcterms:extent":"171 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9ZAYHU9A/2955961a-4c99-401a-b463-6e6d390136ad/TEXT","dcterms:extent":"27 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-9ZAYHU9A","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2005","dc:creator":"Oven, Irena","dc:format":[{"@xml:lang":"sl","#text":"letnik:39"},{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"8 strani"},{"@xml:lang":"sl","#text":"str. 261-268"}],"dc:identifier":["ISSN:1318-2099","COBISSID:1837704","URN:URN:NBN:SI:doc-9ZAYHU9A"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"sl","#text":"imunoterapija"},{"@xml:lang":"sl","#text":"onkologija"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"sl","#text":"tumorji"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"MHC class II molecules and tumour immunotherapy|"},"dc:description":[{"@xml:lang":"sl","#text":"Tumour immunontherapy attempts to use the specificity and capability of the immune system to kill malignant cells with a minimum damage to normal tissue.n Increasing knowledge of the identity of tumour antigens should help us design more effective therapeutic vaccines. Increasing evidence has demonstrated that MHC class II molecules and CD4+T cells play important roles in generating and maintaining antitumour immune responses in animal models. These data suggest that be necessary to involve both CD+ and CD+T cells for more effective antitumour therapy. Novel strategies have been developed for enhancing T cell responses against cancer by prolonging antigen prersentation of denritic cells to T cells, by the inclusion of MHC class II-restricted tumour antigens and by genetically modifying tumour cells to present antigen to T lymphocytes directly. Vaccines against cancers aim to induce tumour-specific effector T cells that can reduce tumour mass and induce development of tumour-specific T cell memory, that can control tumour relapse"},{"@xml:lang":"sl","#text":"Izhodišča. Imunoterapija tumorjev izrablja sposobnost imunskega sistema, da se specifično ubija tumorske celice, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih celic, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih antigenov prispeva k načrtovanju bolj učinkovitih terapevtskih cepiv. Študije narejene na živalskih modelih so pokazale, da so poleg molekul MHC I in celic CD8+ T pri nastanku in vzdrževanju imunskega odziva proti tumorjem pomembne tudi molekuleMHC II in celice CD4+ T. Rezultati nakazujejo, da bo za učinkovito protitumorsko cepivo potrebno aktivirati tako celice CD4+ kot tudi CD8+ T. V zadnjem času so se razvile nove strategije za okrepitev T celičnega odgovora proti raku, ki izrabljajo sposobnost dendritienih celic, da delujejo kot antigeni. Z vključevanjem tumorskih antigenov specifičnih za molekule MHC II in z genetičnim spreminjanem tumorskih celic, da delujejo kot antigeni (antigen-predstavitvene celice), lahko podaljšamo predstavljanje antigenov celicam T preko dendritičnih celic. Zaključki. Z združitvijo različnih pristopov bi lahko naredili učinkovito protitumorsko cepivo, ki bi vzpodbudilo delovanje za tumor specifičnih celic T, te pa bi ubile tumorske celice. S tem bi zmanjšale obseg tumorja, obenem pa bi vzpodbudile tudi nastanek za tumor specifičnega celičnega spomina T, ki bi omejil ali preprečil ponovni nastanek tumorja"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-9ZAYHU9A","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-9ZAYHU9A"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-9ZAYHU9A/b4f6eca3-5f56-4e04-abb3-b88c151cf527/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-9ZAYHU9A/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-9ZAYHU9A"}}}}